A novel Bruton's tyrosine kinase inhibitor JDB175 shows potent efficacy to suppress central nervous system lymphoma
Abstract Patients with central nervous system (CNS) lymphoma face limited treatment options and poor treatment outcomes, emphasizing the urgent need for effective therapeutic strategies. One limiting factor contributing to the suboptimal efficacy is the inadequate penetration of most treatment drugs...
Main Authors: | Yong Xia, Xue Li, Ning Jiang, Xiawei Wei |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2023-12-01
|
Series: | MedComm |
Subjects: | |
Online Access: | https://doi.org/10.1002/mco2.424 |
Similar Items
-
Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review
by: Jing Shen, et al.
Published: (2022-11-01) -
Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases
by: Liang Wang, et al.
Published: (2021-04-01) -
Targeting Bruton’s tyrosine kinase in vitreoretinal lymphoma: an open-label, prospective, single-center, phase 2 study
by: Wenxue Guan, et al.
Published: (2022-11-01) -
Targeting Bruton Tyrosine Kinase: A novel strategy in the treatment of B-cell lymphomas
by: Sklavenitis-Pistofidis R., et al.
Published: (2017-06-01) -
Bruton’s Tyrosine Kinase Inhibitors (BTKIs): Review of Preclinical Studies and Evaluation of Clinical Trials
by: Dariusz Rozkiewicz, et al.
Published: (2023-03-01)